# Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

> **NCT00081536** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Aronex Pharmaceuticals** · enrollment: 105 (—)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Aroplatin (Liposomal NDDP) in combination with capecitabine

## Key facts

- **NCT ID:** NCT00081536
- **Lead sponsor:** Aronex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 105 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081536, "Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00081536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*